What is DF/HCC?

Dana-Farber/Harvard Cancer Center (DF/HCC) is an NCI-designated comprehensive cancer center that unites the cancer research efforts of five Boston academic medical institutions—Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital—and two Harvard Schools—the Harvard Medical School and the Harvard T.H. Chan School of Public Health. 

Am I a part of it?

If you are working on oncology research at one of the member institutions listed above, then you are a part of DF/HCC.

What does that mean for my research?

Please review the DF/HCC Protocol Review Requirements to determine whether your research must be submitted to DF/HCC. Applicable research projects are subject to DF/HCC policies and must comply with DF/HCC requirements, including the following:

Note - There may be additional institution-specific requirements and processes that also apply. Contact your institutional clinical trials office for guidance.